PrEP for Women in Australia: What You Need to Know About HIV Prevention
%20Medium.jpeg)
When most Australians hear the term PrEP, they think of gay men. That association is understandable. For the better part of a decade, public health campaigns, clinical guidelines, and media coverage around pre-exposure prophylaxis have been directed overwhelmingly at men who have sex with men. Those campaigns have been remarkably successful. Australia has seen significant reductions in new HIV diagnoses among MSM communities, driven in large part by widespread PrEP uptake, early treatment, and undetectable viral load strategies.
But the focus on one population has come at a cost. Women have been largely absent from the PrEP conversation in Australia, despite the fact that heterosexual transmission remains a pathway for HIV acquisition. According to the Kirby Institute's most recent annual surveillance data, heterosexual contact continues to account for a meaningful proportion of new HIV diagnoses in Australia each year. Among those diagnosed through heterosexual contact, women represent a significant share. These are not abstract statistics. They represent women who may have benefited from a prevention option that was available, effective, and largely invisible to them.
The gap is not one of eligibility. PrEP has been listed on the Pharmaceutical Benefits Scheme since 2018 and is available to any Australian at risk of HIV, regardless of gender or sexual orientation. The gap is one of awareness, clinical confidence, and public health messaging that has not yet caught up with the evidence. This guide is written specifically for women in Australia who want to understand what PrEP is, whether it may be relevant to their circumstances, and how to access it through a GP.
PrEP stands for pre-exposure prophylaxis. It is a preventive medication taken by people who do not have HIV but who may be at risk of acquiring it. The tablet contains two antiretroviral medicines, emtricitabine and tenofovir disoproxil, which work together to prevent HIV from establishing an infection in the body if the person is exposed to the virus.
The mechanism is straightforward. When taken consistently, the active ingredients in PrEP build up in the tissues where HIV would typically take hold, including mucosal tissue and blood cells. If HIV enters the body through sexual contact, the medication blocks the virus from replicating and establishing a permanent infection. Without the ability to replicate, the virus is cleared by the immune system before it can take root.
The clinical evidence supporting PrEP is substantial. International trials, including the Partners PrEP Study conducted among heterosexual serodiscordant couples in Africa, demonstrated that daily PrEP reduced the risk of HIV acquisition by over 90 percent when taken consistently. When adherence is high, meaning the tablet is taken every day as prescribed, clinical data shows that the risk reduction exceeds 99 percent. These figures are drawn from large, well-designed randomised controlled trials and have been endorsed by the World Health Organization, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), and the Australian Government Department of Health.
It is important to understand what PrEP is not. It is not a cure for HIV. It is not effective if taken inconsistently or only occasionally. It does not protect against other sexually transmitted infections. And it is not a substitute for other prevention strategies such as barrier methods. PrEP is one tool in a broader prevention approach, and it works best when combined with regular STI screening, open communication with sexual partners, and ongoing GP care.
PrEP is not intended for everyone. It is a targeted prevention strategy for people whose circumstances place them at higher risk of HIV exposure. For women in Australia, there are several situations in which PrEP may be worth discussing with a GP.
Women who have a sexual partner living with HIV may benefit from PrEP, particularly if that partner is not currently on effective antiretroviral treatment or has not yet achieved an undetectable viral load. While an undetectable viral load means HIV cannot be transmitted sexually, there are periods during treatment initiation or lapses in adherence when transmission risk may exist. PrEP provides an additional layer of protection during those periods.
Women who have multiple sexual partners, or whose partners have multiple sexual partners, may also be candidates for PrEP. The more sexual contacts involved, the greater the statistical likelihood of encountering HIV, particularly when the HIV status of all partners is not known. This is not a moral assessment. It is an epidemiological reality that applies regardless of relationship structure or personal choices.
Women who have been diagnosed with a sexually transmitted infection in the past twelve months are considered at elevated risk for HIV acquisition. STIs can cause inflammation and breaks in mucosal tissue, which may increase susceptibility to HIV during sexual contact. A recent STI diagnosis is one of the clinical indicators that Australian prescribing guidelines specifically identify as a reason to discuss PrEP.
Women who do not consistently use barrier protection during sexual contact may also benefit from PrEP. Condoms remain one of the most effective methods for preventing both HIV and other STIs, but real-world adherence to condom use varies, and there are circumstances in which barrier methods may not be used or may fail. PrEP offers protection in those situations.
Sex workers in Australia face occupational exposure risks that make PrEP a relevant consideration, and many sexual health services already include PrEP in their standard of care for sex workers.
Women who have come from, or have sexual partners from, regions with higher HIV prevalence may also wish to discuss PrEP with their GP. Sub-Saharan Africa, parts of South-East Asia, and the Caribbean have higher rates of heterosexual HIV transmission than Australia, and migration patterns mean these considerations are relevant within the Australian clinical context.
Ultimately, the decision about whether PrEP is appropriate is one for a woman and her GP to make together. The criteria above are not a checklist to be applied rigidly. They are starting points for a clinical conversation about individual risk.
Accessing PrEP in Australia requires a prescription from a GP or a sexual health physician. It is not available over the counter. The prescribing process involves a clinical assessment to confirm eligibility, establish baseline health markers, and ensure that PrEP is appropriate for the individual.
The first step is a consultation with a GP. During this appointment, your doctor will discuss your sexual health history, assess your risk factors for HIV, and explain how PrEP works. This conversation is confidential, clinical, and entirely routine for GPs who prescribe PrEP. If you feel uncertain about raising the topic, it can help to know that ASHM actively encourages GPs to initiate conversations about PrEP with patients who may benefit from it, so you are not asking for something unusual.
Before prescribing PrEP, your GP will order a series of baseline tests. These typically include an HIV test to confirm that you are HIV-negative, as PrEP must not be started in someone who already has HIV. Kidney function tests are required because the medication is processed through the kidneys, and baseline kidney health needs to be established before commencing treatment. Hepatitis B serology is checked because the active ingredients in PrEP also have activity against hepatitis B, and stopping PrEP in someone with hepatitis B requires medical supervision. A standard STI screen, including tests for chlamydia, gonorrhoea, and syphilis, is also part of the baseline assessment.
Once the results are reviewed and your GP is satisfied that PrEP is appropriate, they will write a prescription. Since April 2018, PrEP has been listed on the Pharmaceutical Benefits Scheme, which means the cost is subsidised by the Australian Government. For patients with a Medicare card, the PBS-subsidised price makes PrEP affordable, and for those with a Health Care Card or Pensioner Concession Card the cost is lower still. Your GP can provide specific pricing information at the time of prescribing.
After the initial prescription, PrEP requires ongoing monitoring. Australian prescribing guidelines recommend follow-up consultations every three months. At each visit, your GP will repeat the HIV test, check kidney function, and conduct STI screening. These regular check-ups serve a dual purpose. They ensure the medication is not causing any adverse effects, and they provide a structured opportunity for regular sexual health screening that many women might not otherwise access.
PrEP is a single tablet taken once daily, at roughly the same time each day. Consistency is the most important factor in its effectiveness. Missing doses reduces the concentration of the medication in the tissues where it is needed, which can lower its protective effect. For women, pharmacokinetic studies suggest that it may take approximately seven days of daily dosing for the medication to reach protective levels in vaginal tissue, compared to a shorter timeframe for rectal tissue. This means that daily adherence is particularly important for women relying on PrEP for protection during vaginal sex.
Side effects, when they occur, are generally mild and tend to resolve within the first few weeks of treatment. The most commonly reported side effects include nausea, headache, and fatigue. Some women experience mild gastrointestinal discomfort during the initial adjustment period. These effects are well documented in clinical trial data and typically settle as the body adjusts to the medication. If side effects persist or are bothersome, your GP can discuss management strategies and assess whether continuing PrEP remains appropriate.
Kidney function is monitored every three months because the medication is cleared through the kidneys. Clinically significant kidney effects are rare in people with healthy baseline kidney function, but regular monitoring ensures any changes are detected early. Your GP manages this through routine blood tests at each quarterly follow-up.
One point that is worth emphasising is that PrEP protects against HIV only. It does not prevent acquisition of other sexually transmitted infections such as chlamydia, gonorrhoea, syphilis, or herpes. Barrier methods, including condoms, remain the most effective way to reduce the risk of these infections and are recommended alongside PrEP. The quarterly STI screening that forms part of PrEP monitoring helps ensure that any other infections are detected and treated promptly, but prevention remains preferable to treatment.
For women who are considering pregnancy, planning to become pregnant, or who discover they are pregnant while taking PrEP, it is essential to discuss this with a GP. Current ASHM guidelines provide advice on PrEP use during pregnancy and breastfeeding, and your doctor can help weigh the benefits of continued HIV prevention against any considerations specific to your situation.
If you are also exploring contraceptive options, it is worth knowing that PrEP does not interact with hormonal birth control options in Australia, including the oral contraceptive pill, implants, and intrauterine devices. PrEP and hormonal contraception can be used safely together.
For women in Australia who want to explore PrEP, getting started does not require a trip to a sexual health clinic or a specialist referral. It starts with a GP consultation, and that consultation can happen online through Abby Health.
Abby Health is an online-first clinic with more than 300 clinicians available seven days a week, 365 days a year. You can book a telehealth consultation from wherever you are in Australia, whether that is a capital city, a regional centre, or a remote community where access to in-person sexual health services may be limited. The consultation takes place over a secure video call with a GP who can assess your eligibility, discuss your individual risk factors, and determine whether PrEP is appropriate for you.
If your GP decides that PrEP is suitable, they will order the necessary baseline pathology tests, which you complete at a local pathology collection centre at a time that suits you. Once results are reviewed, your GP can send your prescription electronically to a pharmacy of your choice. The entire process, from consultation to prescription, is designed to be straightforward and private.
The quarterly follow-up appointments that PrEP requires are well suited to telehealth. Every three months, you consult with your GP for the required HIV test, kidney function check, and STI screen. Your doctor orders the pathology, you attend a collection centre, and results are reviewed at your next consultation. There are no waiting rooms, no need to take time off work, and no need to explain the purpose of your visit to anyone other than your GP.
Consultations through Abby Health can be bulk billed for eligible patients. Because Abby's care model is built around continuity, you see the same GP for your follow-ups, which means you are not repeating your history or re-establishing trust with a new clinician every three months. That continuity matters for something as personal as sexual health. Our data shows that three in four patients see the same clinician again, because the care model is designed to make that the default rather than the exception.
If you are considering PrEP, or simply want to have the conversation with a GP to understand whether it is relevant to your circumstances, you can book a consultation through our Women's Health clinic. You do not need a referral. You just need to be willing to have the conversation.
Editorial Standards
Notice something that doesn’t look right? Let us know at support@abbyhealth.app
Authors
